MESO Mesoblast Limited

10.63
+0.06  (+1%)
Previous Close 10.57
Open 10.88
Price To Book 2.23
Market Cap 1,061,255,468
Shares 99,835,886
Volume 149,232
Short Ratio
Av. Daily Volume 60,017
Stock charts supplied by TradingView

NewsSee all news

  1. Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco

    NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today reported that the United States Food and Drug

  2. Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L

    MELBOURNE, Australia and NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in cellular medicines for inflammatory diseases, announced that the United States Food and

  3. Data Monitoring Committee Completes Final Scheduled Review of Mesoblast's Phase 3 Trial of Revascor in Advanced Chronic Heart Failure

    NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) announced today that the independent Data Monitoring Committee (DMC) overseeing the Phase 3 trial of Revascor for advanced chronic

  4. Mesoblast's Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion

    NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) today announced that its Phase 3 trial of Revascor for advanced chronic heart failure has surpassed the number of primary endpoint

  5. Mesoblast Finanical Results for the Quarter Ended September 30, 2019

    MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO) today reported operational highlights and financial results for the first quarter ended September 30, 2019.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b Class IV primary endpoint reached 1Q 2018.
MPC-150-IM - Class IV
Chronic heart failure (CHF)
Phase 3 last patient visit 1H 2020. Data estimate mid-2020.
MPC-06-ID
Chronic low back pain
BLA rolling submission has been initiated. Final part to be filed in January 2020.
Remestemcel-L (MSC-100-IV)
acute graft versus host disease (aGVHD) in children
Phase 2 data released August 2016. Partnership required for Phase 3 development.
MPC-300-IV
Rheumatoid arthritis
Phase 3 data due mid-2020.
MPC-150-IM - Class 2/3
Heart failure
Phase 2b trial did not meet primary endpoint - November 11, 2018.
MPC-150-IM
End-Stage Heart Failure with LVADs

Latest News

  1. Mesoblast Presents Commercial Plans at 2020 Biotech Showcase in San Francisco

    NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today reported that the United States Food and Drug

  2. Mesoblast Submits Clinical Efficacy And Safety Data To FDA In Rolling Biologics License Application For Remestemcel-L

    MELBOURNE, Australia and NEW YORK, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO), global leader in cellular medicines for inflammatory diseases, announced that the United States Food and

  3. Data Monitoring Committee Completes Final Scheduled Review of Mesoblast's Phase 3 Trial of Revascor in Advanced Chronic Heart Failure

    NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) announced today that the independent Data Monitoring Committee (DMC) overseeing the Phase 3 trial of Revascor for advanced chronic

  4. Mesoblast's Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion

    NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) today announced that its Phase 3 trial of Revascor for advanced chronic heart failure has surpassed the number of primary endpoint

  5. Mesoblast Finanical Results for the Quarter Ended September 30, 2019

    MELBOURNE, Australia and NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited ((ASX:MSB, NASDAQ:MESO) today reported operational highlights and financial results for the first quarter ended September 30, 2019.

  6. Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended September 30, 2019

    NEW YORK and MELBOURNE, Australia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the

  7. Mesoblast Completes Successful Institutional Capital Raising of A$75 Million

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)), leader in cellular medicines for inflammatory diseases, announced today that it has successfully completed a A$75 million (US$50.4

  8. Mesoblast Corporate Update: Analyst Call

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will provide a corporate update during an analyst call today. The

  9. Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

    AACHEN, Germany, and MELBOURNE, Australia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Grünenthal, a global leader in pain management, and Mesoblast Limited ((ASX: MSB, NASDAQ:MESO), a world leader in allogeneic cellular

  10. Mesoblast Reports 2019 Full Year Results

    NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX: MSB)) today reported strong operational progress and financial highlights for the fourth quarter and full-year

  11. Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019

    NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss the

  12. FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD

    NEW YORK and MELBOURNE, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in cellular medicines for inflammatory diseases, announced today positive outcomes from its